Advancing Precision Depigmentation Through Real-World Learnings in Vitiligo

Time: 9:15 am
day: Day One AM

Details:

• Key outcomes and safety insights from adult and adolescent trials investigating topical JAK inhibition in vitiligo
• Translating clinical success to pediatric populations and adapting protocols for less extensive disease
• Navigating operational and regulatory challenges including enrollment barriers and long-term data expectations
• Applying lessons from atopic dermatitis programs to improve trial design, endpoint strategy, and FDA alignment in vitiligo

Speakers:

Diana Stefani-Hunyady Diana Stefani-Hunyady, MD, MBA, BCMAS is a senior medical affairs leader with 25 years of global experience spanning pharma, biotech, and devices. She has led Read more